SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer

• Status: RECRUITING
• Trial end date: 2027-02-28

Summary

To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer.

• Phase: NA

Details

• Lead Sponsor: The First People's Hospital of Lianyungang